EUVIMEDEUVIMED entdecken
Crossref

A Translational Tool to Facilitate Use of Apolipoprotein B for Clinical Decision-Making

Justine Cole iD, James Dorian Otvos, Alan Thomas Remaley

Clinical Chemistry · 2023

DOI: 10.1093/clinchem/hvac161 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Chemistry, 2023. Verfasst von Justine Cole und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Cholesterol, Atherosclerosis. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite recent large-scale discordance studies showing definitively that atherosclerotic cardiovascular disease (ASCVD) risk correlates better with apolipoprotein B (apoB) than with low-density lipoprotein cholesterol (LDL-C), the latter remains the recommended metric for guiding lipid-lowering treatment decisions in the United States. A major barrier to change, in this regard, is the lack of guideline-recommended apoB treatment targets. We developed a simple method to “translate” apoB values into population-equivalent LDL-C units, allowing apoB-based treatment decisions to be made using LDL-C targets.

Methods

Sequentially collected, population-based samples underwent standard lipid panel analysis and apoB testing by immunoassay. Those with triglycerides greater than 1000 mg/dl were excluded, leaving a study cohort of 15 153 individuals.

Results

Linear regression of calculated LDL-C values against percentile-equivalent apoB values yielded an equation to convert apoB into percentile-equivalent LDL-C units: [LDL-C equivalents = 1.38(apoB) – 29] (R2 = 0.999). The extent of discordance between LDL-C and apoB was examined in subgroups with similar LDL-C, ranging from very low (55–70 mg/dL) to very high (175–190 mg/dL). Among individuals with very low LDL-C, 40% had discordantly higher apoB, indicating higher ASCVD risk. Of those with very high LDL-C, 49% had discordantly lower apoB. Across the range, a minority of patients (25%–40%) had concordant levels of apoB, confirming that discordance between these biomarkers is highly prevalent. Similar results were found in discordance analysis between apoB and non-high-density lipoprotein cholesterol (HDL-C).

Conclusions

Providing visibility to discrepancies among LDL-C, non-HDL-C, and apoB should help to facilitate more rapid and widespread adoption of apoB for managing ASCVD risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholesterolAtherosclerosisHumansCholesterol, LDLApolipoproteins BTriglyceridesLipoproteinsClinical Decision-MakingCholesterol, HDL

Stichwörter der Autor:innen

LDL-Capolipoprotein Batherosclerotic cardiovascular diseasecholesterollipids

Substanzen

Cholesterol, LDLCholesterolApolipoproteins BTriglyceridesLipoproteinsCholesterol, HDL

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
  • Labcorp, Morrisville, NC, USA.
  • Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

ORCID-Profile: Justine Cole

Zitieren

APA

Cole, J., Otvos, J. D., & Remaley, A. T. (2023). A Translational Tool to Facilitate Use of Apolipoprotein B for Clinical Decision-Making. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvac161

Vancouver

Cole J, Otvos JD, Remaley AT. A Translational Tool to Facilitate Use of Apolipoprotein B for Clinical Decision-Making. Clinical Chemistry. 2023. doi:10.1093/clinchem/hvac161

BibTeX
@article{Cole2023,
  author = {Cole, Justine and Otvos, James Dorian and Remaley, Alan Thomas},
  title = {A Translational Tool to Facilitate Use of Apolipoprotein B for Clinical Decision-Making},
  journal = {Clinical Chemistry},
  year = {2023},
  doi = {10.1093/clinchem/hvac161}
}
Kostenlos starten →